Friday, August 7, 2026 - Week 32 CAMP4 - Gaining momentum - Approval for trials in Australia & +$50M of cash from investors:investors.camp4tx.com/news-releases/news-release-details/camp4-therapeutics-secures-australian-regulatory-clearance - Profile on CNBC Cures: cnbc.com/2026/08/06/camp4-advances-rare-disease-treatment-for-syngap1-into-human-trials.html Where they mentioned approval in Argentina! $CAMP closed at $4.53 yesterday. google.com/finance/beta/quote/CAMP:NASDAQ MAKE SURE YOU ARE REGISTERED WITH CONNECT curesyngap1.org/curesyngap1connect USA 🇺🇲: Use your ICD-10, F78.A1 CITIZEN Sign up now! citizen.health/ai-advocate/syngap1 SOCIAL MATTERS 5,156 LinkedIn. linkedin.com/company/curesyngap1 1.6k YouTube. youtube.com/@CureSYNGAP1 11.1k Twitter twitter.com/cureSYNGAP1 43.7k Insta instagram.com/curesyngap1 Like and subscribe to this podcast wherever you listen. curesyn...